SEC Comment Letter for Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Feb 4, 2019
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Feb. 4, 2019 · CIK: 0001671502 · Accession: 0000000000-19-000772
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229083
Letter
February 1, 2019 Shai Yarkoni Chief Executive Officer Cellect Biotechnology Ltd. 23 Hata’as Street Kfar Saba, Israel 44425 Re:Cellect Biotechnology Ltd. Registration Statement on Form F-1 Filed December 28, 2018 File No. 333-229083 Dear Dr. Yarkoni: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Caleb French at 202-551-6947 with any questions. Sincerely, Division of Corporation Finance Office of Electronics and Machinery cc: Gary Emmanuel, Esq.
Show Raw Text
February 1, 2019
Shai Yarkoni
Chief Executive Officer
Cellect Biotechnology Ltd.
23 Hata’as Street
Kfar Saba, Israel 44425
Re:Cellect Biotechnology Ltd.
Registration Statement on Form F-1
Filed December 28, 2018
File No. 333-229083
Dear Dr. Yarkoni:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Caleb French at 202-551-6947 with any questions.
Sincerely,
Division of Corporation Finance
Office of Electronics and Machinery
cc: Gary Emmanuel, Esq.